Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Epidemiology of Chondrosarcoma in Iran Based on Iran National Cancer Registry Publisher



Ebrahimpour A1 ; Chehrassan M2 ; Karimi A3 ; Sabaghzadeh A1 ; Kafiabadi MJ1 ; Biglari F1 ; Looha MA4 ; Nakhostinansari A5, 6 ; Sadighi M1 ; Akbari ME7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Orthopedics Department, Shohada Tajrish Hospital, Medical School, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Orthopedic Surgery, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Department of Biostatics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Sports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Neuromusculoskeletal Research Center, Iran University of Medical Sciences, Tehran, Iran
  7. 7. Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: International Journal of Cancer Management Published:2022


Abstract

Background: Chondrosarcoma is regarded as the second most common primary bone malignancy following osteosarcoma. Objectives: The present study aimed at determining the epidemiology, incidence, and survival rate of chondrosarcoma in the Ira-nian population, according to the Iran National Cancer Registry (INCR). Methods: In an epidemiological study, patients with limb chondrosarcoma were evaluated based on INCR data between 2008 and 2015. Data included patients’ demographic characteristics, date of diagnosis, location of the tumor, patient’s survival, and type of tumor based on the International Classification of Diseases for Oncology (ICD-O-3; first revision, third edition) were collected and analyzed. Results: Out of 732 enrolled patients, 425 patients (58.06%) were male and 307 (41.94%) were female with a mean age of 44.08 (SD = 19.31) and 45.06 (SD = 18.72), respectively. Age-standardized incidence rates (ASIR) were 1.73 and 1.27 per 1 million person-years for males and females, respectively. Conventional chondrosarcoma was the most common subtype with ASIR 1.28 and constituted 84.7% of patients with chondrosarcoma. About 71.03% of all Chondrosarcoma patients (70.35% of males and 71.99% of females) were between 20 to 59 years old. The 1-, 3-, 5-, and 7-year survival rates of patients were 0.87, 0.73, 0.57, and 0.47, respectively. Also, the mean survival time was 6.12 years (95% CI: 5.85-7.39). Conclusions: The incidence of chondrosarcoma in Iran is not as high as in other countries, but as patients are younger in Iran, the survival rate is worse compared to other countries. Therefore, better case findings and better care are needed to improve the patients’ outcomes in Iran. © 2022, Author(s).
Related Docs
1. Incidence of Primary Bone Sarcomas in Iranian Population (2008-2015): A National Population-Based Study, Caspian Journal of Internal Medicine (2022)
2. Geographical and Socioeconomic Inequalities in Female Breast Cancer Incidence and Mortality in Iran: A Bayesian Spatial Analysis of Registry Data, PLoS ONE (2021)
3. Clinical Breast Cancer Registry of Ir. Iran (Cbcr-Ir): Study Protocol and First Results, Archives of Iranian Medicine (2023)
4. Pancreatic Cancer in Iran - Result of the Iranian National Cancer Registry Program, Asian Pacific Journal of Cancer Prevention (2022)
5. Establishment of Iran Musculoskeletal Tumor Registry: A Study Protocol and Lessons Learned From Implementation and the Pilot Phase, Medical Journal of the Islamic Republic of Iran (2023)
6. Esophageal and Gastric Cancer Incidence Trends in Golestan, Iran: An Age-Period-Cohort Analysis 2004 to 2018, International Journal of Cancer (2023)
7. Colorectal Cancer Incidence Trends in Golestan, Iran: An Age-Period-Cohort Analysis 2004–2018, Cancer Epidemiology (2023)
8. Building Cancer Registries in a Lower Resource Setting: The 10-Year Experience of Golestan, Northern Iran, Cancer Epidemiology (2018)
Experts (# of related papers)
View all Related Experts
Reza Malekzadeh (3)
Kazem Zendehdel (2)